Circulating tumour DNA
Liquid biopsy with ctDNA for detection, monitoring and treatment decisions.
Key point
ctDNA testing may be used when tissue testing is challenging, infeasible, risky, delayed, or required by drug indication; negative/inconclusive results should prompt tissue confirmation.
From: Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline (JCO Oncol Pract, 2026 Sep) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 225, 244, 260, 252, 328.
New guidelines and consensus this year
- Clinical Practice Guidelines for Pleural Effusion and Bronchoalveolar Lavage Fluid-Based Circulating Tumor DNA Testing in Lung CancerAnn Lab Med2026 Oct 8
- [GFCO national recommendations on the use of liquid biopsy for circulating tumor DNA analysis in oncology]Bull Cancer2026 Oct
- Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO GuidelineJCO Oncol Pract2026 Sep
- Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research GroupJ Thorac Oncol2026 Aug
- Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statementGynecol Oncol2026 Jan
All papers from the last 12 months
2,393 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Digital droplet PCR and liquid biopsy in acute myeloid Leukemia: bridging translational research and clinical practiceClin Chim Acta2027 Feb 15PMID 42624191Review
- PCR and molecular diagnostics: Biotechnologic integration in clinical laboratoriesClin Chim Acta2027 Feb 15PMID 42586250Review
- Multiplex methylation marker analysis for ctDNA detection in liquid biopsies from anal cancer patients: an HPV-independent approachClin Chim Acta2027 Feb 15PMID 42392486
- Development of multi-functional TICT-based fluorescent probe for micro viscosity and latent fingerprint detectionSpectrochim Acta A Mol Biomol Spectrosc2027 Jan 15PMID 42748720
- Quality assessment, prognostic factors, and biomarkers for brain tumor analysis: a comprehensive systematic reviewClin Chim Acta2027 Jan 1PMID 42362136Systematic review
- Evaluating circulating tumor DNA methylation patterns of a multi-gene panel for colorectal cancer diagnosis: A pilot studyClin Chim Acta2027 Jan 1PMID 42320666
- Microfluidic biosensors for early detection of ovarian cancerClin Chim Acta2027 Jan 1PMID 42288273Review
- Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumorsJ Liq Biopsy2026 DecPMID 42871719
- Circulating MicroRNAs in non-small cell lung cancer: Clinical potential, analytic pitfalls, and barriers to implementationJ Liq Biopsy2026 DecPMID 42840427Review
- Cerebrospinal fluid circulating tumor DNA profiling in central nervous system metastases from solid tumors: A prospective multicentre translational analysis of the BrainStorm (OncoDistinct-006) studyJ Liq Biopsy2026 DecPMID 42835688
More oncology trends
All specialties →Claudin 18.2
Claudin 18.2 as a target in gastric and oesophageal cancer.
Key point: Zolbetuximab is recommended for patients with gastroesophageal adenocarcinoma, PD-L1 <1, and positive CLDN18.2 expression.
Antibody-drug conjugates
Antibodies linked to chemotherapy, such as trastuzumab deruxtecan.
Key point: Recent positive phase III trial data have further incorporated ADCs into standard of care in several solid tumours, while predictive biomarker development remains essential.
Perioperative immunotherapy
Immune checkpoint inhibitors given before and after cancer surgery.
Bispecific antibodies in solid tumours
Bispecific antibodies such as tarlatamab, amivantamab and ivonescimab.
Personalised cancer vaccines
mRNA and neoantigen vaccines tailored to a patient's tumour.
AI in cancer pathology
Deep learning on digital pathology slides.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
ctDNA[tiab] OR "circulating tumor DNA"[tiab] OR "circulating tumour DNA"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.